- Home
- VERO vs RDHL Comparison
VERO vs RDHL Comparison
Compare VERO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- RDHL
- Stock Information
- Founded
- VERO N/A
- RDHL 2009
- Country
- VERO Canada
- RDHL Israel
- Employees
- VERO N/A
- RDHL N/A
- Industry
- VERO Medical/Dental Instruments
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- RDHL Health Care
- Exchange
- VERO Nasdaq
- RDHL Nasdaq
- Market Cap
- VERO 4.5M
- RDHL 3.9M
- IPO Year
- VERO N/A
- RDHL N/A
- Fundamental
- Price
- VERO $2.25
- RDHL $1.45
- Analyst Decision
- VERO
- RDHL
- Analyst Count
- VERO 0
- RDHL 0
- Target Price
- VERO N/A
- RDHL N/A
- AVG Volume (30 Days)
- VERO 43.0K
- RDHL 92.2K
- Earning Date
- VERO 08-14-2025
- RDHL 09-05-2025
- Dividend Yield
- VERO N/A
- RDHL N/A
- EPS Growth
- VERO N/A
- RDHL N/A
- EPS
- VERO N/A
- RDHL N/A
- Revenue
- VERO $60,107,000.00
- RDHL $9,550,000.00
- Revenue This Year
- VERO N/A
- RDHL $381.91
- Revenue Next Year
- VERO $7.51
- RDHL N/A
- P/E Ratio
- VERO N/A
- RDHL N/A
- Revenue Growth
- VERO N/A
- RDHL 157.62
- 52 Week Low
- VERO $2.10
- RDHL $1.06
- 52 Week High
- VERO $14.50
- RDHL $12.50
- Technical
- Relative Strength Index (RSI)
- VERO 42.08
- RDHL 52.27
- Support Level
- VERO $2.18
- RDHL $1.22
- Resistance Level
- VERO $2.34
- RDHL $1.49
- Average True Range (ATR)
- VERO 0.16
- RDHL 0.08
- MACD
- VERO -0.01
- RDHL 0.03
- Stochastic Oscillator
- VERO 21.36
- RDHL 85.19
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.